!-- notag -->
Press Releases - 2019 - Sanofi
Worldwide presence
English
English
français
Media
MMMM D, YYYY
Press Releases 2019
Home
Media
Press releases
2019
Press Releases - 2019
Facebook
Twitter
LinkedIn
Download the PDF version
2019-12-23
MMMM DD YYYY
Press releases
Sanofi commences tender offer for acquisition of Synthorx, Inc.
Download the PDF version
2019-12-10
MMMM DD YYYY
Press releases
Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Download the PDF version
2019-12-10
MMMM DD YYYY
Press releases
Sanofi : Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
Download the PDF version
2019-12-09
MMMM DD YYYY
Press releases
Sanofi CEO unveils new strategy to drive innovation and growth
Download the PDF version
2019-12-09
MMMM DD YYYY
Press releases
Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
Download the PDF version
2019-11-04
MMMM DD YYYY
Press releases
Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
Download the PDF version
2019-11-04
MMMM DD YYYY
Press releases
Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
Download the PDF version
2019-10-31
MMMM DD YYYY
Press releases
Sanofi Q3 well on track
Download the PDF version
2019-10-31
MMMM DD YYYY
Press releases
Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation
Download the PDF version
2019-10-29
MMMM DD YYYY
Press releases
Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
Download the PDF version
2019-10-15
MMMM DD YYYY
Press releases
Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing
Download the PDF version
2019-10-01
MMMM DD YYYY
Press releases
Sanofi : Availability of the Pre-quarterly Results Communication
Download the PDF version
2019-09-30
MMMM DD YYYY
Press releases
Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
Download the PDF version
2019-09-20
MMMM DD YYYY
Press releases
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis
Download the PDF version
2019-09-16
MMMM DD YYYY
Press releases
Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
2019-08-28 22-35-00-1908076-en
2019-08-28
MMMM DD YYYY
Press releases
Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
Download the PDF version
2019-08-06
MMMM DD YYYY
Press releases
Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
Download the PDF version
2019-08-06
MMMM DD YYYY
Press releases
Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
Download the PDF version
2019-07-29
MMMM DD YYYY
Press releases
Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019
Download the PDF version
2019-07-29
MMMM DD YYYY
Press releases
Sanofi delivered solid growth in Q2 2019
Download the PDF version
2019-07-26
MMMM DD YYYY
Press releases
Sanofi : Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
Download the PDF version
2019-07-26
MMMM DD YYYY
Press releases
Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
Download the PDF version
2019-07-23
MMMM DD YYYY
Press releases
Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care
Download the PDF version
2019-07-10
MMMM DD YYYY
Press releases
Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
Download the PDF version
2019-07-02
MMMM DD YYYY
Press releases
Sanofi : Availability of the Pre-quarterly Results Communication
Download the PDF version
2019-07-01
MMMM DD YYYY
Press releases
Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
Download the PDF version
2019-06-28
MMMM DD YYYY
Press releases
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Download the PDF version
2019-06-27
MMMM DD YYYY
Press releases
Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate
Download the PDF version
2019-06-26
MMMM DD YYYY
Press releases
Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
Download the PDF version
2019-06-21
MMMM DD YYYY
Press releases
Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
Download the PDF version
2019-06-18
MMMM DD YYYY
Press releases
Sanofi and Google to develop new healthcare Innovation Lab
Download the PDF version
2019-06-09
MMMM DD YYYY
Press releases
Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
Download the PDF version
2019-06-07
MMMM DD YYYY
Press releases
Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
Download the PDF version
2019-06-02
MMMM DD YYYY
Press releases
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
Download the PDF version
2019-05-07
MMMM DD YYYY
Press releases
Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
Download the PDF version
2019-04-30
MMMM DD YYYY
Press releases
Sanofi: Annual General Meeting of April 30, 2019
Download the PDF version
2019-04-27
MMMM DD YYYY
Press releases
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
Download the PDF version
2019-04-26
MMMM DD YYYY
Press releases
ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
Download the PDF version
2019-04-26
MMMM DD YYYY
Press releases
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
Download the PDF version
2019-04-26
MMMM DD YYYY
Press releases
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
Download the PDF version
2019-04-08
MMMM DD YYYY
Press releases
Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
Download the PDF version
2019-04-01
MMMM DD YYYY
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
Download the PDF version
2019-03-22
MMMM DD YYYY
Press releases
Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
Download the PDF version
2019-03-15
MMMM DD YYYY
Press releases
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Download the PDF version
2019-03-13
MMMM DD YYYY
Press releases
Sanofi successfully prices EUR 2 billion of bond issues
Download the PDF version
2019-03-08
MMMM DD YYYY
Press releases
Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
Download the PDF version
2019-03-08
MMMM DD YYYY
Press releases
Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
Download the PDF version
2019-03-01
MMMM DD YYYY
Press releases
Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
Download the PDF version
2019-03-01
MMMM DD YYYY
Press releases
Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes
Download the PDF version
2019-02-25
MMMM DD YYYY
Press releases
Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies
Download the PDF version
2019-02-25
MMMM DD YYYY
Press releases
Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Download the PDF version
2019-02-12
MMMM DD YYYY
Press releases
Sanofi appoints Ameet Nathwani Chief Digital Officer
Download the PDF version
2019-02-07
MMMM DD YYYY
Press releases
Sanofi delivers 2018 business EPS growth of 5.1% at CER
Download the PDF version
2019-02-06
MMMM DD YYYY
Press releases
Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
Download the PDF version
2019-02-06
MMMM DD YYYY
Press releases
Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Download the PDF version
2019-02-05
MMMM DD YYYY
Press releases
Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
Download the PDF version
2019-02-04
MMMM DD YYYY
Press releases
Sanofi : CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Download the PDF version
2019-01-30
MMMM DD YYYY
Press releases
Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
Download the PDF version
2019-01-18
MMMM DD YYYY
Press releases
Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes
Download the PDF version
2019-01-11
MMMM DD YYYY
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
Download the PDF version
2019-01-09
MMMM DD YYYY
Press releases
New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder
Download the PDF version
2019-01-07
MMMM DD YYYY
Press releases
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
!-- notag -->